Shares of Jazz Pharmaceuticals Inc. plunged Monday after a panel of Food and Drug Administration experts recommended the company's proposed chronic pain disorder treatment not be approved.
THE SPARK: On Friday, the panel said sodium oxybate shouldn't be approved as a treatment for the chronic pain condition fibromyalgia because of risks that it could be dangerously abused. The drug is already approved under the name Xyrem to treat excessive sleepiness. It is considered a "controlled substance," by the U.S. drug enforcement authorities because its active ingredient has been used as an illegal stimulant and as a date rape drug.
Monday, August 23, 2010
Jazz shares fall after negative FDA panel vote - Yahoo! Finance
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment